PALLD Antibody

What are the common applications for PALLD antibodies in research settings?

PALLD antibodies have been validated for multiple research applications with specific protocols and dilution requirements. Primary applications include:

For optimal results, titration of the antibody is recommended for each specific application and sample type. For IHC applications, antigen retrieval using TE buffer pH 9.0 is suggested, with citrate buffer pH 6.0 as an alternative option .

What are the various isoforms of Palladin and how can they be detected?

Palladin exists in multiple isoforms with varying molecular weights:

• 65 kDa: Observed in normal pancreas and non-PDA (pancreatic ductal adenocarcinoma) tumors

• 85-90 kDa: Predominantly expressed in PDA samples

• 95 kDa, 115 kDa, and 140 kDa: Detected in various cell lines including HeLa, 293T, PC-3, and Caki-2

• 151 kDa: The calculated full-length protein

Western blot detection requires careful selection of antibodies, as some are isoform-specific. For instance, the 1E6 monoclonal antibody is isoform-selective, while the 622 polyclonal antibody detects multiple isoforms . When investigating palladin in cancer contexts, it's crucial to use antibodies that can differentiate between the 65 kDa and 85-90 kDa isoforms, as their expression patterns differ between normal pancreatic tissue and PDA .

How should I select the appropriate PALLD antibody for my research?

Selection criteria should include:

• Target specificity: Consider which isoform(s) you need to detect. Some antibodies like the 1E6 monoclonal are isoform-specific, while polyclonal antibodies may detect multiple isoforms .

• Host species compatibility: Available options include:

  • Mouse monoclonal (IgG2a) - e.g., 66601-1-Ig

  • Rabbit polyclonal - e.g., 10853-1-AP

  • Sheep polyclonal - e.g., AF5950

• Species reactivity: Confirm the antibody has been validated for your species of interest:

  • 66601-1-Ig: Human, rat, pig

  • 10853-1-AP: Human, mouse (with citations for rat reactivity)

  • AF5950: Human

• Application compatibility: Ensure the antibody has been validated for your specific technique (WB, IHC, IF, etc.) .

How should I optimize Western blot protocols for detecting different Palladin isoforms?

When optimizing Western blot protocols for Palladin isoforms:

• Protein extraction: Use Immunoblot Buffer Group 1 under reducing conditions, as demonstrated for detection of 95, 115, and 140 kDa isoforms in multiple cell lines .

• Gel percentage: Due to the wide range of Palladin isoform sizes (65-151 kDa), use gradient gels (4-12%) or lower percentage gels (7-8%) to achieve optimal separation.

• Antibody selection: For detecting multiple isoforms simultaneously, use polyclonal antibodies. For example:

  • AF5950 at 0.5 μg/mL detected bands at 95, 115, and 140 kDa in HeLa, 293T, PC-3, and Caki-2 cell lines

  • The 622 polyclonal antibody detected both 65 kDa and 85-90 kDa isoforms in pancreatic tissues

• Positive controls: Include well-characterized samples:

  • For the 85-90 kDa isoform: PDA samples

  • For the 65 kDa isoform: Normal pancreas tissue

  • For multiple isoforms: HeLa or 293T cells

• Membrane type: PVDF membranes have been successfully used for Palladin detection .

What are the recommended protocols for immunohistochemical detection of Palladin in different tissues?

For optimal IHC detection of Palladin:

• Fixation and embedding: Use standard formalin fixation and paraffin embedding procedures.

• Antigen retrieval:

  • Primary recommendation: TE buffer at pH 9.0

  • Alternative method: Citrate buffer at pH 6.0

  • For specific tissues like prostate, heat-induced epitope retrieval using basic antigen retrieval reagent has been successful

• Antibody concentration and incubation:

  • For polyclonal antibodies (e.g., AF5950): 10 μg/mL for 1 hour at room temperature

  • For monoclonal and rabbit polyclonal antibodies: Dilution ranges of 1:50-1:500

• Detection systems: Anti-Sheep IgG VisUCyte HRP Polymer Antibody has been successfully used with DAB (brown) staining, followed by hematoxylin (blue) counterstaining .

• Tissue-specific considerations:

  • In prostate tissue: Palladin staining localizes to smooth muscle cells

  • In cancer tissues: Differential expression patterns between normal and malignant tissues should be anticipated

How can I design experiments to study the role of Palladin in cell migration and cancer invasion?

To investigate Palladin's role in cancer cell migration and invasion:

• Expression manipulation strategies:

  • siRNA knockdown: This approach has been successfully used to deplete Palladin and study its effects on cell behavior

  • Overexpression of specific isoforms: Focus on the 85-90 kDa isoform that is upregulated in PDA

• Phenotypic assays:

  • Cell migration assays: Wounds healing or transwell assays

  • Invasion assays: Matrigel-coated transwells

  • Morphology analysis: Actin cytoskeleton visualization using phalloidin staining alongside Palladin immunofluorescence

• Molecular interaction studies:

  • Co-immunoprecipitation: Can be performed using 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

  • Confocal microscopy: Using IF protocols with dilutions of 1:50-1:500

• Control experiments:

  • Rescue experiments using constitutively active AKT1 or dominant negative GSK3β, which have been shown to rescue Palladin depletion-induced phenotypes

  • Comparative analysis between PDA and non-PDA samples to correlate isoform expression with invasive potential

How does Palladin regulate mitotic spindle orientation, and what techniques can be used to investigate this function?

Palladin has been identified as a novel MT-associated protein that regulates spindle orientation and mitotic progression through the AKT1-GSK3β pathway . To investigate this function:

• Live-cell imaging: Monitor mitotic progression in Palladin-depleted cells compared to controls, focusing on:

  • Duration of metaphase, which is prolonged with Palladin depletion

  • Spindle orientation angles, which are distorted in Palladin-deficient cells

• Immunofluorescence analysis:

  • Co-stain for Palladin (using antibodies at 1:50-1:500 dilution) and tubulin to visualize mitotic spindles

  • Quantify astral microtubule stability, which is compromised with Palladin depletion

• Molecular pathway investigation:

  • Test if constitutively active AKT1 or dominant negative GSK3β can rescue the phenotypes of Palladin depletion

  • Analyze phosphorylation status of GSK3β as a downstream effect of Palladin function

• Cell proliferation assays:

  • Quantify proliferation rates in relation to Palladin expression, as Palladin depletion impairs proliferation of HeLa cells

• Experimental design considerations:

  • Include proper controls for siRNA experiments

  • Use multiple cell types to determine if the mechanism is conserved across different contexts

  • Consider the contribution of different Palladin isoforms to this function

What are the optimal experimental designs for studying Palladin in complex tissue microenvironments?

When investigating Palladin in complex tissue microenvironments:

• Experimental design optimization:

  • Implement a "repeated measures" design that allows sampling from the same system (e.g., chip) multiple times

  • Account for technical confounders (operator, control unit) through careful experimental arrangement

  • Apply mixed-model analysis pipelines to increase statistical power

• Multicolor flow cytometry:

  • Develop panels that can accurately identify both cell lineage and maturation stage

  • Use 0.40 μg of antibody per 10^6 cells in a 100 μl suspension for intracellular Palladin detection

  • Quantify treatment effects with resolution down to the maturity level of cells

• Microfluidic-based organ systems (MPS):

  • Consider using bone marrow MPS models to study lineage-specific effects

  • Scale experiments appropriately based on power calculations to maximize value from expensive and time-consuming studies

• Spatial analysis in tumor microenvironments:

  • Use IHC with recommended dilutions (1:50-1:500) to analyze Palladin expression patterns in different cellular compartments

  • Compare expression in epithelial versus stromal components, as Palladin may have roles in tumor microenvironment alterations rather than directly within cancer cells

How can Palladin isoform expression be leveraged in cancer diagnostics, particularly for pancreatic ductal adenocarcinoma?

Palladin isoform expression shows specific patterns in pancreatic cancer that could be diagnostically valuable:

• Isoform-specific detection strategies:

  • Use isoform-selective antibodies (e.g., 1E6 monoclonal) for specific detection

  • Employ Western blot analysis to differentiate between the 65 kDa isoform (predominant in normal pancreas) and 85-90 kDa isoform (predominant in PDA)

• Differential diagnosis approaches:

  • Compare expression patterns between PDA and non-PDA tumors (solid pseudopapillary tumors, neuroendocrine carcinomas)

  • The 85-90 kDa isoform is predominantly expressed in PDA while non-PDA tumors express mainly the 65 kDa isoform

• Correlation with invasiveness:

  • Analyze Palladin isoform expression in relation to tumor invasiveness and metastatic potential

  • Non-PDA tumors with lower metastatic potential (e.g., solid pseudopapillary tumors) show different Palladin expression patterns compared to more aggressive PDA

• Validation strategies:

  • Use multiple detection methods (WB, IHC, IF) to confirm isoform expression

  • Include diverse control tissues and multiple antibodies for cross-validation

  • Correlate with clinical outcomes to establish prognostic value

• Technical considerations:

  • For IHC applications in diagnostics, standardize antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Establish scoring systems based on intensity and distribution of staining

What are the latest advances in antibody design that might improve PALLD antibody specificity and applications?

Recent developments in antibody engineering could enhance PALLD antibody performance:

• Novel design tools:

  • FlowDesign offers improved modeling for designing antibodies' Complementarity-Determining Regions (CDRs)

  • This approach has demonstrated better binding affinity and neutralizing potency compared to state-of-the-art antibodies against other targets

• Application to isoform-specific detection:

  • New antibody engineering approaches could potentially develop more selective antibodies for specific Palladin isoforms

  • This would be particularly valuable for distinguishing between the 65 kDa and 85-90 kDa isoforms in cancer diagnostics

• Conjugated antibodies for advanced applications:

  • Consider using fluorophore-conjugated antibodies (e.g., CoraLite® Plus 488, CoraLite®555, CoraLite®594) for direct detection in IF experiments

  • These eliminate the need for secondary antibodies, reducing background and cross-reactivity

• Validation methodologies:

  • Implement comprehensive validation pipelines including Biolayer interferometry (BLI) to evaluate binding affinity

  • Consider pseudovirus neutralization evaluation techniques as models for validation